Epidaza (chidamide)

These findings suggest that the BTG1/BECN1/ATG5 signaling axis plays a critical role in enhancing autophagy and reversing Rituximab resistance. The combination of Chidamide and Rituximab presents a promising therapeutic strategy, offering new insights into overcoming drug resistance in DLBCL.

P2, N=60, Recruiting, Shanghai Changzheng Hospital

P2, N=160, Recruiting, Chinese PLA General Hospital

P=N/A, N=30, Recruiting, Dongguan Kanghua Hospital; Dongguan Kanghua Hospital

P3, N=140, Recruiting, Beijing Cancer Hospital/The First Affiliated Hospital of Zhejiang University School of Medicine; Hangzhou HealZen Therapeutics Co., Ltd

P2, N=50, Recruiting, Fujian Medical University Union Hospital; Fujian Medical University Union Hospital

P2, N=42, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University

P2, N=223, Not yet recruiting, The Affiliated Hospital of Qingdao University; the Affiliated Hospital of Qingdao University

P1/2, N=12, Terminated, Henan Cancer Hospital | N=28 --> 12 | Trial completion date: Jan 2027 --> Feb 2025 | Recruiting --> Terminated; The clinical development of parsaclisib was stopped by it's manufacturer.

P2, N=128, Not yet recruiting, Li Zhiming

P2, N=148, Recruiting, The First Affiliated Hospital with Nanjing Medical University

P2, N=22, Recruiting, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> May 2025

Between October 2021 and July 2023, 24 patients aged 41 to 88 years (median, 73.4 years) who had undergone prior therapies, including intensive chemotherapy (79.2%) and mogamulizumab immunotherapy (79.2%), received tucidinostat. Treatment-related adverse events were mainly hematologic but were managed over the course of treatment. Our findings indicate that tucidinostat provides survival benefits in patients with relapsed/refractory ATL in clinical practice and highlight key clinical factors for better outcomes.

P1/2, N=7, Terminated, Great Novel Therapeutics Biotech & Medicals Corporation | N=46 --> 7 | Trial completion date: Jan 2026 --> Jan 2025 | Recruiting --> Terminated; The overall profile does not support development for Hepatocellular Carcinoma

P=N/A, N=200, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

P2, N=130, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Compound 55 demonstrated good antitumor activity in vivo. Specifically, compound 55 combined with chidamide demonstrated a superior therapeutic effect over the first-line therapy RTX-CHOP in both the DEL and TP53 mutant DLBCL PDX tumor models.

P2, N=21, Active, not recruiting, The First Affiliated Hospital of Soochow University | Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Dec 2024 --> Dec 2026

P2, N=33, Recruiting, The First Affiliated Hospital of Xiamen University | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2026

P=N/A, N=400, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting

P2, N=33, Recruiting, The First Affiliated Hospital of Xiamen University | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2027

P2, N=30, Recruiting, Shanghai Jiao Tong University School of Medicine | Trial primary completion date: Jan 2025 --> Jan 2026

This study not only elucidates the biological function of lactylated METTL3 in tumor cells but also highlights its negative regulatory effect on cisplatin resistance. Additionally, it underscores the nonclassical functional mechanism of Tucidinostat as a HDAC inhibitor for improving the efficacy of cisplatin against TNBC.

Here, by screening a library of marketed drugs, we identified Chidamide had a strong binding affinity toward VISTA (KD = 5 nM) and blocked VISTA/PSGL-1 under acidic conditions, thereby significantly enhancing the function of CD8+ T cells and inhibiting the tumor growth in immunocompetent murine CT26 tumor model. This study represents the first discovery of Chidamide as VISTA/PSGL-1 blocker for cancer immunotherapy.

Co-treatment with an FAO inhibitor etomoxir enhanced the combined effects of chidamide with established chemotherapy drugs, as well as their efficacy as single agents in TNBC cells. In conclusion, FAO likely exerts pleiotropic biological effects in TNBC and modulating FAO may offer a promising strategy to improve therapeutic outcomes in TNBC.

Following two VCA courses, he received chimeric antigen receptor T-cell therapy, which led to complete metabolic remission and improved prognosis. This case underscores the potential of the VCA regimen as a bridging therapy for EMR in B-ALL with MLL-AF4, although further studies are warranted.

P2, N=17, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University | N=30 --> 17

In vivo experiments showed that infusion of CD19 CAR T cells after chidamide bridging intervention can enhance the therapeutic effect of B-NHL and prolong the overall survival of mice. This study provides a new direction and theoretical foundation for CD19 CAR T cell therapy in B-NHL.

P=N/A, N=54, Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University

P2, N=32, Fudan University Shanghai Cancer Center Urology; Fudan University Shanghai Cancer Center Urology

P=N/A, N=400, Not yet recruiting, Ruijin Hospital

P3, N=120, Not yet recruiting, Evopoint Biosciences Inc.

P2, N=30, Recruiting, First Affiliated Hospital of Ningbo University

P1/2, N=45, Not yet recruiting, Peking University Cancer Hospital & Institute

P2, N=50, Recruiting, First Affiliated Hospital of Ningbo University

P2, N=37, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Trial primary completion date: Mar 2026 --> Dec 2026

Lastly, our experimental validation demonstrated the ability of the histone deacetylase (HDAC) inhibitor chidamide to activate the PPAR signal in TNBC cells. In conclusion, the PPAR signaling pathway likely has pleiotropic biological effects in TNBC. These preliminary but interesting findings enhance our understanding of the role played by PPAR signal and provide new insights into the heterogeneity driven by it in TNBC.

P2, N=34, Not yet recruiting, Ruijin Hospital

P2, N=63, Not yet recruiting, Peking University

P1, N=9, Terminated, Taipei Medical University Shuang Ho Hospital | Trial completion date: Dec 2024 --> Mar 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Mar 2024; The overall profile does not support development for metastatic colorectal cancer

P2, N=300, Recruiting, Tianjin Medical University Second Hospital

Notably, genes commonly mutated in AITL, including RHOA, TET2, DNMT3A, and IDH2, were absent in this case. A review of the literature highlights the heterogeneous genomic landscape of AITL and the diversity of treatment options available, underscoring the importance of tailored approaches to overcome resistance and improve outcomes in this distinct lymphoma subtype.